List of Excipients in Branded Drug PHENYTOIN INFATABS

« Back to Dashboard

Generic Drugs Containing PHENYTOIN INFATABS

Company	Ingredient	NDC	Excipient
NCS HealthCare of KY LLC dba Vangard Labs	phenytoin	0615-8260	ALUMINUM OXIDE
NCS HealthCare of KY LLC dba Vangard Labs	phenytoin	0615-8260	D&C YELLOW NO. 10
NCS HealthCare of KY LLC dba Vangard Labs	phenytoin	0615-8260	FD&C YELLOW NO. 6

What are the Most Frequently-Used Excipients in PHENYTOIN INFATABS?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
2	D&C YELLOW NO. 10
3	D&C YELLOW NO. 10 ALUMINUM LAKE

Phenytoin Infatabs Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Phenytoin Infatabs is a legacy 50 mg phenytoin sodium chewable tablet whose commercial value depends on formulation execution rather than active-ingredient exclusivity. The strongest opportunities are an authorized-generic or generic chewable product, pediatric-friendly excipient optimization, pharmacy substitution, and hospital supply reliability. The principal risks are phenytoin’s narrow therapeutic index, nonlinear pharmacokinetics, excipient-driven bioequivalence issues, and a mature market with limited pricing power.

What is Phenytoin Infatabs and how is it formulated?

Phenytoin Infatabs is a chewable dosage form containing 50 mg of phenytoin sodium per tablet. It is associated with the Dilantin product family and is intended for patients who have difficulty swallowing conventional tablets or require a lower unit dose than standard extended phenytoin sodium capsules.[1]

The formulation platform must deliver four commercial functions:

1. Accurate 50 mg phenytoin sodium dosing.
2. Acceptable taste and mouthfeel.
3. Physical stability during storage and handling.
4. Comparable absorption to the reference product.

Public product labeling identifies inactive ingredients used in the chewable tablet, including conventional tablet excipients such as confectioner's sugar, cellulose-based diluents, magnesium stearate, sodium lauryl sulfate, coloring agents, and other formulation components depending on the marketed version and labeling revision.[1] The exact reference formulation should be confirmed against the applicable FDA-approved package insert and current product listing before development or litigation use.

Why the excipient system matters

Phenytoin is a weakly acidic, poorly water-soluble compound with clinically important exposure variability. Its pharmacokinetics are nonlinear, meaning relatively small changes in dose or bioavailability can produce disproportionate changes in plasma concentration.[2]

For a chewable tablet, excipient selection can affect:

• Wetting and dissolution of phenytoin sodium.
• Tablet disintegration after chewing.
• Powder flow and content uniformity.
• Taste masking.
• Tablet hardness and friability.
• Sodium load and ionic microenvironment.
• Stability under humidity and temperature stress.
• In vitro and in vivo comparability to the reference product.

A generic sponsor cannot treat the excipient system as a cosmetic variable. Changes in surfactant level, lubricant concentration, particle-size distribution, compression force, or sweetener system can alter dissolution and potentially affect bioequivalence.

What excipients are commercially important in a phenytoin chewable tablet?

The commercial formulation strategy should separate functional excipients from patient-experience excipients.

Excipient function	Candidate strategy	Primary development issue
Diluent	Microcrystalline cellulose, lactose, sugar-based diluent, mannitol	Bulk density, compressibility, dissolution
Sweetener	Sucrose, mannitol, sucralose, acesulfame potassium	Taste, dental positioning, hygroscopicity
Binder	Povidone, copovidone, starch-based binder	Granule strength and disintegration
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Chewability and dissolution
Wetting agent	Sodium lauryl sulfate or alternative surfactant	Solubility, taste, irritation risk
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection force and dissolution impact
Flavor	Fruit or confectionery flavor system	Patient acceptance and stability
Colorant	Approved synthetic or mineral colorant	Product identity and regulatory compliance
Glidant	Colloidal silicon dioxide or talc	Flow, segregation, and content uniformity

A sugar-based system can support palatability but may create humidity, dental, and packaging challenges. Mannitol can provide a cleaner mouthfeel and lower hygroscopicity, but it can alter tablet compactability and cooling sensation. A low-sugar or sugar-free formulation could create a differentiated pediatric product, although the clinical and regulatory advantage would need to justify development cost.

What excipient changes create the greatest regulatory risk?

The highest-risk changes are those affecting dissolution, wetting, particle dispersion, and tablet disintegration. In phenytoin, a formulation that dissolves faster or slower than the reference product can create exposure differences that are clinically relevant despite apparently minor manufacturing changes.

Risk increases when a sponsor changes:

• Surfactant identity or concentration.
• Drug substance particle size.
• Granulation method.
• Compression profile.
• Lubrication time.
• Sweetener from sugar to polyol.
• Disintegrant type or level.
• Coating or taste-masking technology.
• Packaging from high-barrier to standard bottles.

A formulation change may require comparative dissolution work, a biowaiver assessment, or a comparative pharmacokinetic study under the applicable FDA abbreviated new drug application pathway. The narrow therapeutic index of phenytoin makes a conservative development program preferable.

What formulation opportunities exist for Phenytoin Infatabs?

Pediatric-friendly chewable tablets

The most direct opportunity is a modernized 50 mg chewable tablet designed for children and adults who cannot swallow capsules. Product differentiation can come from:

• Better flavor masking.
• Lower tablet hardness.
• Reduced chalkiness.
• Improved dose flexibility.
• Unit-dose packaging.
• Clearer administration instructions.
• Reduced sugar content.
• Age-appropriate tablet dimensions.

The formulation must remain a true chewable product. A tablet that requires prolonged chewing, leaves a gritty residue, or has a strong medicinal aftertaste is commercially vulnerable even if it meets laboratory specifications.

Lower-sugar and sugar-free products

A sugar-free product could target chronic-use patients, pediatric caregivers, and institutions seeking lower excipient burdens. Mannitol, xylitol, or other polyols can support this strategy, but each introduces development questions involving hygroscopicity, cooling effect, gastrointestinal tolerance, and compression behavior.

Xylitol can be attractive from a dental perspective but creates manufacturing and labeling considerations. Mannitol is generally more established in chewable tablets but may produce a different mouthfeel from the reference product. A sponsor should prioritize dissolution and clinical comparability over sensory differentiation where the two objectives conflict.

Scored or flexible-dose presentation

A 50 mg tablet can support dose titration, but a scored design must be validated for subdivision if the product is intended to be split. Phenytoin dosing is patient-specific, and clinicians often adjust doses based on serum concentrations, albumin status, drug interactions, and clinical response.[2]

A scored tablet could have commercial value if it produces reliable half-tablet dosing. The product claim must be supported by split-tablet testing, including weight variation, content uniformity, and stability of divided units where required.

Unit-dose and institutional packaging

Hospitals, long-term-care facilities, correctional systems, and specialty pharmacies may value blister packaging and unit-dose cartons. Packaging can reduce medication errors and support controlled administration in pediatric and neurologic-care settings.

The packaging strategy should address:

• Moisture protection.
• Child-resistant requirements.
• Unit-dose labeling.
• Lot traceability.
• Tablet identification.
• Protection from crushing or accidental mixing.
• Storage conditions after opening.

For a low-volume legacy product, packaging reliability can be a stronger differentiator than branding.

What is the FDA regulatory status of Phenytoin Infatabs?

Phenytoin Infatabs is an established prescription drug product. FDA-approved phenytoin products include capsules, extended-release capsules, oral suspension, injectable formulations, and chewable tablets.[1,3]

The main regulatory issues are dosage-form equivalence and bioequivalence. A sponsor developing a generic chewable product must determine the applicable reference listed drug and confirm whether the reference product remains commercially available, discontinued, or eligible for an alternative reference pathway.

FDA guidance treats phenytoin as a drug requiring careful bioequivalence analysis because of its pharmacokinetic characteristics and therapeutic index.[2] The sponsor should expect scrutiny of:

• Comparative dissolution across pH conditions.
• Drug-release profiles.
• Assay and content uniformity.
• Particle-size distribution.
• Stability.
• Inactive-ingredient safety.
• In vivo pharmacokinetic comparability, where required.

What is the Orange Book status of Phenytoin Infatabs?

Phenytoin is an old active ingredient, and the original composition, formulation, and use patents associated with early Dilantin products are expired or no longer relevant to market entry. The principal current barrier is therefore FDA approval and manufacturing capability, not an active composition-of-matter patent.

Orange Book status must be assessed using the current FDA publication and the specific reference listed drug. A historical absence of active patent listings does not eliminate regulatory exclusivity, product-specific exclusivity, or listing differences among dosage forms.[3]

When does Phenytoin Infatabs lose exclusivity?

Phenytoin’s basic active-ingredient exclusivity expired decades ago. A generic sponsor’s principal pathway is an ANDA referencing the applicable FDA-listed product.

Exclusivity category	Strategic assessment
Active-ingredient patent	Expired
Original formulation patents	Generally expired
Method-of-use patents	No practical barrier expected for standard seizure indications
Orange Book patent protection	Must be checked against the current listing
New generic exclusivity	Possible only for a qualifying first applicant
Pediatric exclusivity	Not expected to create a current barrier for this legacy product
Biosimilar exclusivity	Not applicable

A Paragraph IV challenge would have limited commercial relevance unless an active later-issued patent were listed against the reference product. For a legacy phenytoin chewable tablet, the more likely route is a standard ANDA without a meaningful patent dispute.

Which companies could challenge or replace Phenytoin Infatabs?

Potential competitors include generic manufacturers with existing oral solid-dose and antiepileptic portfolios. Relevant capabilities include:

• Chewable-tablet manufacturing.
• High-potency or low-dose content uniformity control.
• Taste-masking technology.
• Pediatric formulation development.
• ANDA regulatory experience.
• U.S. commercial distribution.

The competitive field is likely to include established generic companies, authorized-generic suppliers, and contract development and manufacturing organizations. The principal competitive advantage will be reliable supply, not patent exclusion.

A sponsor with an existing phenytoin capsule or oral-suspension product could obtain portfolio synergies through shared active-ingredient sourcing, quality systems, pharmacovigilance, and specialty-pharmacy distribution. A company without a neurology portfolio would face higher commercial costs because the product is unlikely to support broad primary-care promotion.

How strong is the patent estate for Phenytoin Infatabs?

The patent estate is weak as a standalone exclusivity platform. Phenytoin sodium is a long-established active ingredient, and the commercial opportunity is not based on blocking patents.

Possible residual intellectual-property assets could include:

• New excipient combinations.
• Taste-masking systems.
• Modified particle-size distributions.
• Manufacturing processes.
• Packaging configurations.
• Pediatric dosage platforms.
• Abuse-deterrent or adherence-oriented presentations.

These assets would need to produce a clinically or commercially meaningful product distinction. A narrow patent covering an ordinary sweetener substitution is unlikely to create durable market power. A stronger patent position would require a demonstrated relationship between the formulation and a measurable benefit, such as improved dissolution consistency, improved palatability, reduced variability, or a specific stability advantage.

What generic launch risks exist for Phenytoin Infatabs?

The market has five principal launch risks.

1. Small addressable market

Most phenytoin use has shifted toward newer antiseizure medicines in many treatment settings. Phenytoin remains relevant in selected epilepsy, emergency, inpatient, and cost-sensitive settings, but the chewable segment is narrower than the total phenytoin market.

2. Narrow therapeutic index

A small bioavailability difference can generate clinical concern. This increases development, regulatory, and post-launch quality costs.

3. Substitution uncertainty

Pharmacy substitution depends on the approved dosage form, strength, therapeutic-equivalence rating, state law, payer policy, and availability of the reference product. A product should not assume automatic substitution without confirming the applicable FDA rating.

4. Low price and high supply expectations

Generic buyers expect low unit cost, while hospitals and pharmacies penalize stockouts. A manufacturer needs efficient packaging, robust API sourcing, and inventory discipline.

5. Patient switching concerns

Patients stabilized on phenytoin may resist formulation changes because of therapeutic monitoring requirements and prior experiences with different phenytoin products. This can slow conversion even when a generic is legally substitutable.

What licensing deals could support a Phenytoin Infatabs opportunity?

A licensing or commercial partnership could involve:

• An authorized-generic arrangement with the originator or current rights holder.
• Acquisition of an existing ANDA.
• Contract manufacturing for a specialty-pharma company.
• Co-promotion through a neurology-focused distributor.
• Regional commercialization rights.
• Pediatric formulation technology licensing.
• Hospital and long-term-care supply agreements.

The most attractive structure would reduce regulatory risk by using an approved product or validated reference-comparable formulation. Licensing a novel taste-masking platform would be less compelling unless the platform supports multiple pediatric products and creates portfolio value beyond phenytoin.

No broad, high-value licensing thesis is apparent from the legacy phenytoin chewable product alone. Commercial value is more likely to arise from manufacturing scale, supply continuity, and portfolio bundling.

How does Phenytoin Infatabs compare with other phenytoin dosage forms?

Dosage form	Primary advantage	Main limitation	Commercial role
Chewable tablet	Pediatric and swallowing convenience	Taste, dissolution, narrow market	Differentiated niche
Extended-release capsule	Established maintenance therapy	Not suitable for all patients	Core oral product
Oral suspension	Flexible liquid dosing	Shake-dependent variability and handling	Pediatric and swallowing-limited patients
Immediate-release capsule	Conventional oral administration	Less flexible for some patients	Generic maintenance use
Injection	Rapid inpatient use	Administration and safety burden	Hospital and emergency use

The chewable tablet should be positioned as a convenience and adherence product, not as a broad replacement for all oral phenytoin products.

Key Takeaways

• Phenytoin Infatabs is a 50 mg phenytoin sodium chewable tablet with a legacy, formulation-sensitive profile.
• The active ingredient and original product patents do not provide a meaningful modern exclusivity barrier.
• The main regulatory challenge is demonstrating reliable equivalence for a narrow-therapeutic-index drug.
• Excipient strategy should focus on dissolution, taste masking, chewability, content uniformity, and stability.
• Sugar-free, pediatric-friendly, scored, and unit-dose presentations offer the clearest product-development opportunities.
• Commercial returns are likely to depend on low-cost manufacturing, reliable supply, and portfolio synergies.
• Patent value is limited unless a new formulation produces a measurable clinical, sensory, or manufacturing advantage.
• Paragraph IV litigation and biosimilar risk are not central to this product.
• The most credible entry strategy is a generic or authorized-generic product supported by institutional and specialty-pharmacy distribution.

FAQs

Can a manufacturer use different excipients from Phenytoin Infatabs?

Yes. An ANDA may use different inactive ingredients if they are permissible, safe, and supported by the required pharmaceutical and bioequivalence data. Excipients that materially change dissolution or absorption create greater regulatory risk.

Is a sugar-free phenytoin chewable tablet commercially viable?

It could be viable as a differentiated pediatric or chronic-use product, but the addressable market is limited. The formulation must preserve acceptable taste, tablet strength, dissolution, and bioequivalence while avoiding excessive manufacturing cost.

Does phenytoin have biosimilar competition?

No. Phenytoin is a small-molecule drug. Competition proceeds through generic-drug pathways rather than the biosimilar pathway.

Can phenytoin chewable tablets be used interchangeably with phenytoin capsules?

Interchangeability depends on the specific product, dosage form, release characteristics, FDA therapeutic-equivalence rating, and prescribing instructions. Phenytoin products should not be treated as automatically interchangeable solely because they contain the same active ingredient.

What is the strongest commercial differentiator for a new Phenytoin Infatabs competitor?

Consistent supply combined with acceptable taste and verified therapeutic equivalence is likely to be more valuable than a narrow formulation patent. Institutional packaging and a dependable pediatric presentation can strengthen the commercial proposition.

References

1. Pfizer Laboratories. (2018). Dilantin Infatabs (phenytoin sodium) chewable tablets: Prescribing information. U.S. Food and Drug Administration labeling archive.

2. U.S. Food and Drug Administration. (2022). Phenytoin sodium: Product-specific guidance for industry. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.